NFKB1 and Alzheimer disease: Some other therapeutic candidates demonstrated neuroprotective effects by reducing inflammatory markers (e.g., NF-κB and TNF-α) while increasing Nrf2 activity in a scopolamine-induced AD model (Faldu and Shah, 2024).